engleski

ApoE genotyping and response to galanthamine in Alzheimer's disease

Objective. This study is undertaken to evaluate the effect of galanthamine, a new cholinesterase inhibitor on cognitive performances in 84 patients with various apoE genotype and Alzheimer's disease during the six moth treatment. Methods. The diagnosis of AD was made on the basis of NINCDS/ADRDN criteria. ApoE4 genotype was determined by PCR procedure. The cognitive performance was assessed MMSE at baseline and six months later. The difference among the groups was statistically analyzedd by ANOVA model and Pearson's X2 test. Results. The MMSE at baseline in all completers was 18.0&#61617; 0.29, whereas the mean value of MMSE after 6 months was 16.4&#61617; 0.31, indicating significant deterioration (p<0.01). Of 84 patients, 14 (16%) were apoE4 homozygous, 41 (49%) were heterozygous, whereas 29 (35%) were apoE4 negative. The significant number of responders was observed among apoE4 homozygous patients (71% ; X2 = 6.89 ; p = 0.032). Conclusion: The subgroup of apoE4 homozygous patients with AD in its mild to moderate stage might be considered as responders on galanthamine.

ApoE gene; galanthamine; Alzheimer's disease

nije evidentirano